What side effects are associated with this type of intervention?

Common treatments for ovarian cancer, particularly those involving chemotherapy agents like paclitaxel, carboplatin, and targeted therapies such as bevacizumab, often result in a range of side effects. Chemotherapy can cause hematologic toxicities such as neutropenia, anemia, and thrombocytopenia, as well as non-hematologic effects like nausea, fatigue, neuropathy, and hair loss. Targeted therapies, including bevacizumab, may lead to hypertension, proteinuria, and increased risk of bleeding and thromboembolic events. These side effects vary in severity and frequency, necessitating close monitoring and supportive care during treatment.

What prior FDA approvals exist?

FDA-approved treatments for ovarian cancer include several biologic agents and immunotherapies. Bevacizumab, an angiogenesis inhibitor, has been approved for use in combination with chemotherapy for advanced ovarian cancer. PARP inhibitors like olaparib, niraparib, and rucaparib have also been approved for maintenance therapy in patients with recurrent ovarian cancer, particularly those with BRCA mutations. Pembrolizumab, an anti-PD-1 monoclonal antibody, has shown promise in treating ovarian cancer with specific genetic markers. These treatments reflect the ongoing shift towards targeted therapies and immunotherapies in the management of ovarian cancer.

What other types of research exist?

Promising novel alternatives for ovarian cancer treatment in 2024 include PARP inhibitors like olaparib and niraparib, which have shown efficacy in patients with BRCA mutations. Additionally, immune checkpoint inhibitors such as pembrolizumab, either alone or in combination with other agents, are being explored for their potential benefits. Bevacizumab, an anti-angiogenic agent, is also a viable option, particularly in combination with chemotherapy.

← Back to Search

Virus Therapy

NM21-1480 for Advanced Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by Numab Therapeutics AG

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new drug called NM21-1480 in adults with advanced solid tumors. Researchers aim to understand how the drug behaves in the body and its potential to help fight cancer.

Who is the study for?

Adults with advanced solid tumors that have progressed after treatment and lack standard therapy options can join. They must be past treatments by at least 2-4 weeks, depending on the cancer type, and recovered from previous therapies' effects. Those with certain cancers or recent immunotherapy, autoimmune diseases, hypersensitivity to drug components, or recent investigational drug use are excluded.

What is being tested?

NM21-1480 is being tested in adults with specific advanced solid tumors. This early-phase trial aims to find the safest dose level, understand how the body processes it, its potential for immune system activation (immunogenicity), and initial signs of effectiveness against the cancer.

What are the potential side effects?

As this is a first-in-human study for NM21-1480, detailed side effects aren't listed but may include typical reactions related to immune-based cancer therapies such as inflammation in organs or infusion-related reactions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Determination of Phase 2 dose of NM21-1480

Maximum Tolerated Dose (MTD) of NM21-1480

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: NM21-1480 Treatment armExperimental Treatment1 Intervention

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for ovarian cancer include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy, such as carboplatin and paclitaxel, works by damaging the DNA of rapidly dividing cancer cells, leading to cell death. Targeted therapies, like bevacizumab, inhibit specific molecules involved in tumor growth and angiogenesis, thereby starving the tumor of nutrients. Immunotherapy, which is being explored in trials like NM21-1480, aims to boost the body's immune system to recognize and destroy cancer cells. These mechanisms are crucial for ovarian cancer patients as they offer multiple avenues to attack the cancer, potentially improving outcomes and providing options when the disease is resistant to standard treatments.

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.